GE gets FDA priority review for imaging agent

Thursday, June 12, 2008 - 14:14 in Health & Medicine

CHICAGO (Reuters) - GE Healthcare, a unit of General Electric Corp, said on Thursday U.S. health regulators granted it priority review on its application for AdreView, a molecular imaging agent for the detection of neuroendocrine tumors in children and adult patients.

Read the whole article on Reuters:Science

More from Reuters:Science

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net